Moxif0.5%

Moxif 0.5% ophthalmic solution is a broad-spectrum fluoroquinolone antibiotic prescribed for the treatment of bacterial conjunctivitis (bacterial "pink eye") caused by susceptible strains of bacteria. Because moxifloxacin covers a wide range of Gram-positive and Gram-negative organisms, it is a commonly chosen first-line topical antibiotic for acute bacterial eye infections.

It is indicated against susceptible strains of the following organisms:

Aerobic Gram-positive microorganisms

• Corynebacterium species
• Micrococcus luteus
• Staphylococcus aureus
• Staphylococcus epidermidis
• Staphylococcus haemolyticus
• Staphylococcus hominis
• Staphylococcus warneri
• Streptococcus pneumoniae
• Streptococcus viridans group

Aerobic Gram-negative microorganisms

• Acinetobacter lwoffii
• Haemophilus influenzae
• Haemophilus parainfluenzae

Other microorganisms

• Chlamydia trachomatis

Intraocular use

As an intraocular injection, moxifloxacin is a highly effective intraocular antibiotic used to help prevent postoperative bacterial endophthalmitis following eye surgery, such as cataract procedures.

Always take medicines according to the advice of a registered physician.

Ophthalmic antibacterial drugs (fourth-generation fluoroquinolone antibiotic).

Moxifloxacin is a fourth-generation fluoroquinolone antibiotic. Its antimicrobial action results from the inhibition of two essential bacterial enzymes: topoisomerase II (DNA gyrase) and topoisomerase IV.

DNA gyrase is an essential enzyme involved in the replication, transcription and repair of bacterial DNA. Topoisomerase IV plays a key role in partitioning chromosomal DNA during bacterial cell division. By blocking both enzymes, moxifloxacin disrupts DNA synthesis and prevents bacteria from multiplying, leading to bacterial cell death (bactericidal activity).

Because moxifloxacin acts on two distinct targets, the likelihood of bacteria developing spontaneous resistance is reduced compared with older quinolones that primarily target a single enzyme. When applied topically to the eye, it achieves high local concentrations at the site of infection with minimal systemic absorption.

Specific drug-drug interaction studies have not been conducted with Moxif 0.5% ophthalmic solution. However, in vitro studies indicate that moxifloxacin does not inhibit the cytochrome P450 isoenzymes CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2.

This suggests that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these enzymes. In addition, because topical ophthalmic use results in very low systemic absorption, clinically significant interactions with oral or systemic medications are uncommon.

To be safe, inform your physician about all prescription medicines, over-the-counter drugs and other eye preparations you are using before starting treatment.

Most side effects of Moxifloxacin ophthalmic solution are mild and temporary. The most frequently reported ocular (eye-related) adverse events, occurring in approximately 1–6% of patients, include:

• Conjunctivitis
• Decreased visual acuity (temporary blurred vision)
• Dry eye
• Keratitis (inflammation of the cornea)
• Ocular discomfort
• Ocular hyperemia (eye redness)
• Ocular pain
• Ocular pruritus (eye itching)
• Subconjunctival hemorrhage
• Tearing (watery eyes)

Non-ocular adverse events reported at a rate of 1–4% include fever, increased cough, infection, otitis media, pharyngitis, rash, and rhinitis.

Most reactions resolve on their own. Contact your physician if any effect is severe, persistent, or if you experience signs of a serious allergic reaction.

Pregnancy

There are no adequate and well-controlled studies of Moxif 0.5% ophthalmic solution in pregnant women. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Pregnant women should use this medication strictly under the supervision of a registered physician.

Lactation

Moxifloxacin has not been measured in human breast milk, though it can be presumed to be excreted. Caution should be exercised when Moxif 0.5% ophthalmic solution is administered to a nursing mother. Consult a physician before use during breastfeeding.

• Topical use only: This medication is for ophthalmic (eye) use only and should not be injected into the eye or taken by mouth unless a specific intraocular preparation is prescribed for surgical use.
• Risk of superinfection: As with other anti-infectives, prolonged use may result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, discontinue use and start alternative therapy.
• Clinical monitoring: Whenever clinical judgment dictates, the patient should be examined with the aid of magnification, such as slit-lamp biomicroscopy, and, where appropriate, with fluorescein staining.
• Contact lenses: Patients should not wear contact lenses if they have signs and symptoms of bacterial conjunctivitis.
• Temporary blurred vision: Vision may be temporarily blurred after application. Do not drive or operate machinery until vision clears.
• Complete the course: Do not stop treatment early even if symptoms improve, to reduce the risk of recurrence and resistance.

Proper storage preserves the potency and safety of Moxifloxacin across all dosage forms. General instructions apply to all: keep out of the reach of children and away from direct sunlight, moisture and excessive heat.

Tablet

• Keep in a dry place, away from light and heat.
• Store in the original blister pack until use.
• Keep out of the reach of children.

Injection (IV Infusion)

• Store below 25°C and protect from light.
• Avoid extreme heat and do not freeze.
• Do not refrigerate; precipitation may occur at low temperatures.
• Discard any unused portion after opening. Keep out of the reach of children.

Ophthalmic (Eye Drops / Ointment)

• Store below 25°C. Do not freeze.
• Keep in a cool, dry place, protected from light.
• Do not touch the dropper tip to any surface, as this may contaminate the preparation.
• Discard the product within one month of first opening.
• Keep out of the reach of children.